Miro1 protein in skeletal muscle linked to insulin resistance in type 2 diabetes
A study published in Nature Communications found that elevated levels of the protein Miro1 in skeletal muscle may contribute to insulin resistance in people with type 2 diabetes. Removing Miro1 restored insulin response in preclinical models, and exercise reduced the protein's levels in patients with type 2 diabetes. The findings suggest Miro1 could be a target for future treatments aimed at improving blood sugar regulation.
Miro1 is a protein located on the outer membrane of mitochondria, the cell's energy-producing structures. Researchers observed higher amounts of it in skeletal muscle from people with type 2 diabetes. The study combined cellular work, preclinical models, and human samples to trace its role.
In preclinical models, eliminating Miro1 restored insulin responsiveness. Among patients with type 2 diabetes, exercise reduced the protein's levels. The research appeared in Nature Communications and involved senior author John P. Kirwan, first author Elizabeth Heintz, and co-corresponding author Christopher Axelrod.
If confirmed, targeting Miro1 could offer a new route to improve blood sugar control for people with type 2 diabetes. Exercise's ability to lower Miro1 may help explain its benefits and support combined lifestyle and future therapies. Such treatments might complement, not replace, existing approaches. Patients, clinicians, and researchers could see new options, though clinical benefits remain uncertain until human trials test safety and effectiveness.